Does EVOLOCUMAB Cause Psychomotor hyperactivity? 13 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Psychomotor hyperactivity have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.0% of all adverse event reports for EVOLOCUMAB.
13
Reports of Psychomotor hyperactivity with EVOLOCUMAB
0.0%
of all EVOLOCUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Psychomotor hyperactivity From EVOLOCUMAB?
Of the 13 reports, 2 (15.4%) required hospitalization, and 1 (7.7%) were considered life-threatening.
Is Psychomotor hyperactivity Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Psychomotor hyperactivity?
METHYLPHENIDATE (617)
QUETIAPINE (412)
ARIPIPRAZOLE (389)
OLANZAPINE (366)
SERTRALINE (288)
MONTELUKAST (282)
RISPERIDONE (277)
LEVETIRACETAM (247)
VENLAFAXINE (214)
LEVOTHYROXINE (211)
Which EVOLOCUMAB Alternatives Have Lower Psychomotor hyperactivity Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE